VEGFA and non-small cell lung carcinoma: Bevacizumab is a humanized monoclonal antibody against VEGF, which has demonstrated improved progression-free survival (PFS) in phase III trials of metastatic breast (15) and renal cancers (16), in addition to prolonged overall survival in metastatic colorectal (17,18) and non-small cell lung cancers (19).